已核实 DOI 相关产品: 27

Copper-cysteamine nanoparticles reprogram mitochondrial fusion to potentiate sonodynamic therapy for hepatocellular carcinoma

Journal 2026 · IF 8 · 发表于 2026 年 8 月 24 日
作者: Minping Zhang,Meitao Liu,Chen Yu,Jiayi Liu,Qiuling Liao,Wanghao Ma,Enhua Xiao,Wei Chen,Xiangyu Chen
阅读全文 在 PubMed 查看

摘要

Hepatocellular carcinoma (HCC) remains a formidable therapeutic challenge due to its high recurrence rate and limited therapeutic options, especially in advanced stages. Sonodynamic therapy (SDT) has emerged as a promising non-invasive approach with deep-tissue penetration capabilities. However, its efficacy is hindered by the lack of efficient, biosafe sonosensitizers and an insufficient understanding of subcellular mechanisms. To address these limitations, we developed copper-cysteamine nanoparticles (Cu-Cy) as a novel nanosonosensitizer. Under ultrasound irradiation, Cu-Cy generate abundant reactive oxygen species (ROS) dominated by singlet oxygen ( 1 O 2 ), inducing potent cytotoxicity in HCC cell lines (IC 50  = 25 μg/mL) and achieving 87.91% tumor growth inhibition in a Huh7 xenograft model following intratumoral administration, without systemic toxicity. Mechanistically, beyond ROS-mediated damage, ultrasound-activated Cu-Cy reprogram mitochondrial dynamics by upregulating the fusion protein mitofusin-2 (MFN2) and downregulating the fission protein dynamin-1-like protein (DNM1L), shifting the balance toward mitochondrial fusion. This fusion-dominated phenotype suppresses cellular proliferation and migration while activating caspase-dependent apoptosis. Critically, MFN2 silencing abolished these therapeutic effects, confirming the pivotal role of mitochondrial fusion in SDT potentiation. Our findings unveil mitochondrial fusion modulation as a novel therapeutic axis to augment SDT efficacy and establish Cu-Cy as an effective sonosensitizer for local HCC treatment in preclinical models.

本研究中使用的阿拉丁产品

27 款产品在本文中被引用